NZ748592A - Treatment for parkinson’s disease - Google Patents
Treatment for parkinson’s diseaseInfo
- Publication number
- NZ748592A NZ748592A NZ748592A NZ74859217A NZ748592A NZ 748592 A NZ748592 A NZ 748592A NZ 748592 A NZ748592 A NZ 748592A NZ 74859217 A NZ74859217 A NZ 74859217A NZ 748592 A NZ748592 A NZ 748592A
- Authority
- NZ
- New Zealand
- Prior art keywords
- 3haloalkyl
- hydrogen
- disease
- halogen
- parkinson
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621019185 | 2016-06-02 | ||
| IN201621019087 | 2016-06-02 | ||
| PCT/IN2017/050224 WO2017208267A1 (en) | 2016-06-02 | 2017-06-02 | Treatment for parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ748592A true NZ748592A (en) | 2025-11-28 |
Family
ID=59388123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ748592A NZ748592A (en) | 2016-06-02 | 2017-06-02 | Treatment for parkinson’s disease |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10849887B2 (OSRAM) |
| EP (2) | EP3463351B1 (OSRAM) |
| JP (1) | JP6974357B2 (OSRAM) |
| KR (1) | KR102508288B1 (OSRAM) |
| CN (1) | CN109475539B (OSRAM) |
| AU (1) | AU2017273415B2 (OSRAM) |
| CL (1) | CL2018003431A1 (OSRAM) |
| CY (1) | CY1125285T1 (OSRAM) |
| DK (1) | DK3463351T3 (OSRAM) |
| ES (1) | ES2914782T3 (OSRAM) |
| HR (1) | HRP20220683T1 (OSRAM) |
| HU (1) | HUE059387T2 (OSRAM) |
| IL (1) | IL263188B (OSRAM) |
| LT (1) | LT3463351T (OSRAM) |
| MX (1) | MX385276B (OSRAM) |
| MY (1) | MY193754A (OSRAM) |
| NZ (1) | NZ748592A (OSRAM) |
| PH (1) | PH12018502457B1 (OSRAM) |
| PL (1) | PL3463351T3 (OSRAM) |
| PT (1) | PT3463351T (OSRAM) |
| RS (1) | RS63243B1 (OSRAM) |
| SG (1) | SG11201810294QA (OSRAM) |
| SI (1) | SI3463351T1 (OSRAM) |
| SM (1) | SMT202200228T1 (OSRAM) |
| UA (1) | UA123018C2 (OSRAM) |
| WO (1) | WO2017208267A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013166295A1 (en) | 2012-05-02 | 2013-11-07 | Georgetown University | Treating neural disease with tyrosine kinase inhibitors |
| EP3463351B1 (en) | 2016-06-02 | 2022-04-27 | Sun Pharma Advanced Research Company Limited | Treatment for parkinson's disease |
| CN110606840A (zh) | 2018-06-15 | 2019-12-24 | 日产化学株式会社 | 5-炔基吡啶化合物的制造方法 |
| CA3120639A1 (en) | 2018-11-20 | 2020-05-28 | Georgetown University | Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders |
| BR112021024835A2 (pt) * | 2019-06-11 | 2022-01-18 | Sun Pharma Advanced Res Co Ltd | Tratamento para sinuclenopatias |
| WO2021030783A1 (en) * | 2019-08-15 | 2021-02-18 | Duke University | Compositions and methods for the treatment cancer and cns disorders |
| JP2023536440A (ja) | 2020-07-31 | 2023-08-25 | サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド | アルツハイマー病の治療のためのｎ’－（２－クロロ－６－メチルベンゾイル）－４－メチル－３－［２－（３－キノリル）エチニル］－ベンゾヒドラジド |
| CA3251516A1 (en) | 2022-05-02 | 2023-11-09 | Sun Pharma Advanced Research Company Limited | Methods of reducing progression of neurodegenerative disease |
| KR20250040552A (ko) | 2023-09-14 | 2025-03-24 | 주식회사 엑소스템텍 | 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103502217B (zh) * | 2011-01-21 | 2015-11-25 | 太阳医药高级研究有限公司 | 包含酪氨酸激酶抑制剂的二芳基乙炔酰肼 |
| WO2013166295A1 (en) | 2012-05-02 | 2013-11-07 | Georgetown University | Treating neural disease with tyrosine kinase inhibitors |
| EA032697B1 (ru) * | 2015-05-18 | 2019-07-31 | Сан Фарма Адвансед Ресёрч Компани Лимитед | Амидогетероарилароилгидразидэтины |
| EP3463351B1 (en) * | 2016-06-02 | 2022-04-27 | Sun Pharma Advanced Research Company Limited | Treatment for parkinson's disease |
-
2017
- 2017-06-02 EP EP17743097.2A patent/EP3463351B1/en active Active
- 2017-06-02 PT PT177430972T patent/PT3463351T/pt unknown
- 2017-06-02 WO PCT/IN2017/050224 patent/WO2017208267A1/en not_active Ceased
- 2017-06-02 US US16/304,914 patent/US10849887B2/en active Active
- 2017-06-02 HR HRP20220683TT patent/HRP20220683T1/hr unknown
- 2017-06-02 PL PL17743097T patent/PL3463351T3/pl unknown
- 2017-06-02 HU HUE17743097A patent/HUE059387T2/hu unknown
- 2017-06-02 RS RS20220497A patent/RS63243B1/sr unknown
- 2017-06-02 JP JP2018563062A patent/JP6974357B2/ja active Active
- 2017-06-02 KR KR1020187034626A patent/KR102508288B1/ko active Active
- 2017-06-02 UA UAA201812407A patent/UA123018C2/uk unknown
- 2017-06-02 SM SM20220228T patent/SMT202200228T1/it unknown
- 2017-06-02 MY MYPI2018002187A patent/MY193754A/en unknown
- 2017-06-02 ES ES17743097T patent/ES2914782T3/es active Active
- 2017-06-02 MX MX2018014944A patent/MX385276B/es unknown
- 2017-06-02 LT LTEPPCT/IN2017/050224T patent/LT3463351T/lt unknown
- 2017-06-02 SI SI201731157T patent/SI3463351T1/sl unknown
- 2017-06-02 AU AU2017273415A patent/AU2017273415B2/en not_active Ceased
- 2017-06-02 CN CN201780044265.3A patent/CN109475539B/zh active Active
- 2017-06-02 DK DK17743097.2T patent/DK3463351T3/da active
- 2017-06-02 SG SG11201810294QA patent/SG11201810294QA/en unknown
- 2017-06-02 NZ NZ748592A patent/NZ748592A/en unknown
- 2017-06-02 EP EP22169420.1A patent/EP4085912A1/en active Pending
-
2018
- 2018-11-21 IL IL263188A patent/IL263188B/en unknown
- 2018-11-22 PH PH12018502457A patent/PH12018502457B1/en unknown
- 2018-11-30 CL CL2018003431A patent/CL2018003431A1/es unknown
-
2020
- 2020-10-01 US US17/061,139 patent/US11583522B2/en active Active
-
2022
- 2022-05-18 US US17/747,472 patent/US11813252B2/en active Active
- 2022-05-27 CY CY20221100369T patent/CY1125285T1/el unknown
-
2023
- 2023-10-11 US US18/378,901 patent/US20240066014A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ748592A (en) | Treatment for parkinson’s disease | |
| ZA202202097B (en) | Amino pyrimidine ssao inhibitors | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| PH12018502427A1 (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| MY196749A (en) | Eif4a-inhibiting compounds and methods related thereto | |
| PH12016502081B1 (en) | Compounds for treating spinal muscular atrophy | |
| MX2017014584A (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| NZ735575A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| MY206763A (en) | Piperidinyl-3-(aryloxy)propanamides and propanoates | |
| NZ752587A (en) | Lsd1 inhibitors and medical uses thereof | |
| CO2019002517A2 (es) | Inhibidores de dopamina–β–hidroxilasa | |
| TN2018000372A1 (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions. | |
| MX2020001875A (es) | Forma polimorfica de tg02. | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| JOP20190163B1 (ar) | منشط nrf2 | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| MX380758B (es) | Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo. | |
| MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. |